ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment Of Metastatic Colorectal C - Pharmaceutical版

本页内容为未名空间相应帖子的节选和存档，一周内的贴子最多显示50字，超过一周显示500字访问原贴

Pharmaceutical版 - ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment Of Metastatic Colorectal C

相关主题
● who bid for Imcolone?	● Drug Industry Sees Big Job Cuts
● 美国制药商百时美施贵宝将裁员4300人	● Bristol-Myers Squibb
● 请问是否有治疗结肠癌的特效药	● BMS cutoff is offical now.
● BMS咋了？	● 药厂工作top layoff list 2007 (转载)
● Pfizer to Cut R&D Jobs, Retreat from Heart-Drug Research	● 请教如何阅读药学实验的文章，endpoints...谢谢。。
● Time for some BMS buyout rumor again - this time Lilly is the suitor?!	● Ahead of the Bell: Will Pfizer buy Wyeth?
● Abbott Opens New R&D Center at UIUC Research Park	● CLSPA Career Symposium 2010 is only 1 week away (limited seats left)
● annual ranking of America's largest corporations---Pharmaceuticals	● FYI

相关话题的讨论汇总
话题: erbitux话题: phase话题: iii话题: colorectal话题: metastatic

进入Pharmaceutical版参与讨论

(共1页)

y******m
发帖数: 14

NEW YORK, Jan. 10 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated (
Nasdaq: IMCL - News) and Bristol-Myers Squibb Company (NYSE: BMY - News)
today announced that a Phase III study of ERBITUX® (cetuximab) plus
FOLFIRI (an irinotecan- based chemotherapy) met the primary endpoint of
increasing median duration of progression-free survival over FOLFIRI alone
in patients with previously untreated metastatic colorectal cancer (mCRC).
More than 1,000 patients were recruited from around the wo

k**a
发帖数: 284

窃以为erbitux还是很有前途的,不过它是egfr的抗体,还是有很大的潜在危险
但是我还是比较看好用antibody治疗癌症

participate

【在 y******m 的大作中提到】

: NEW YORK, Jan. 10 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated (
: Nasdaq: IMCL - News) and Bristol-Myers Squibb Company (NYSE: BMY - News)
: today announced that a Phase III study of ERBITUX® (cetuximab) plus
: FOLFIRI (an irinotecan- based chemotherapy) met the primary endpoint of
: increasing median duration of progression-free survival over FOLFIRI alone
: in patients with previously untreated metastatic colorectal cancer (mCRC).
: More than 1,000 patients were recruited from around the wo

(共1页)

进入Pharmaceutical版参与讨论

相关主题
● FYI	● Pfizer to Cut R&D Jobs, Retreat from Heart-Drug Research
● Asking for opinions	● Time for some BMS buyout rumor again - this time Lilly is the suitor?!
● BMS Cuts R&D Jobs	● Abbott Opens New R&D Center at UIUC Research Park
● Bristol-Myers Squibb principle或research scientist 工资水平大概在多	● annual ranking of America's largest corporations---Pharmaceuticals
● who bid for Imcolone?	● Drug Industry Sees Big Job Cuts
● 美国制药商百时美施贵宝将裁员4300人	● Bristol-Myers Squibb
● 请问是否有治疗结肠癌的特效药	● BMS cutoff is offical now.
● BMS咋了？	● 药厂工作top layoff list 2007 (转载)

相关话题的讨论汇总
话题: erbitux话题: phase话题: iii话题: colorectal话题: metastatic

#	版面	帖数(主题数)
-	全站	4871 (796)
1	Military	3777 (569)
2	Stock	341 (51)
3	Joke	117 (17)
4	History	116 (3)
5	Automobile	100 (9)
6	USANews	55 (9)
7	Midlife	45 (1)
8	Headline	41 (41)
9	Dreamer	33 (13)
10	FleaMarket	32 (20)
11	Living	30 (7)

boards

未名新帖统计// 7月16日

历史上的今天